http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : osa T. C. (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Multi-Quasiparticle States in Odd-Odd 118I
C.-B. Moon,이춘식,M. Oshima,Y. Toh,J. Goto,Y. Hatsukawa,A. Kimura,M. Koizumi,A. Osa,T. Komatsubara,K. Miyakawa 한국물리학회 2008 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.53 No.4
The excited states of the doubly odd nucleus 118I have been studied by using in-beam γ-ray spectroscopy with the 110Cd(12C, p3n) reaction at Elab = 80 MeV. We have established several multi-quasiparticle states associated with different proton and neutron quasiparticle configurations. A I* = 14- level at 2561 keV was newly observed and found to be associated with the πh11/2υd5/2 configuration coupled to a pair of protons in the g7/2 orbital. TRS calculations for the 14- level indicated a favored oblate state based on the fully aligned four-quasiparticle π[h11=2(g7/2)2]23/2-υ[d5/2]5/2+ configuration. Another energetically favored state I* = 24- at 6216 keV could be interpreted as a noncollective oblate state from the fully aligned six-quasiparicle π[h11/2(g7/2)2]23/2-υ[d5/2(h11/2)2]25/2+ configuration. No Δ = 1 side band of the same parity as the πh11/2υh11/2 band was observed while a side band built on the πg9/2υh11/2 configuration was considered to be caused by the γ vibration coupling.
-
Microneedle-Mediated Transdermal Delivery of Bevacizumab
Courtenay, Aaron J.,McCrudden, Maelí,osa T. C.,McAvoy, Kathryn J.,McCarthy, Helen O.,Donnelly, Ryan F. American Chemical Society 2018 Molecular pharmaceutics Vol.15 No.8
<P>Bevacizumab is a recombinant humanized monoclonal antibody used clinically as a combination chemotherapeutic. Antibody therapeutics are usually formulated as parenteral injections, owing to their low oral bioavailability. Microneedle technology provides a transdermal alternative for drug-delivery using micron-scale needle structures to penetrate directly through the <I>stratum corneum</I> into the dermal interstitium. This study describes the design, formulation, and <I>in vitro</I> characterization of both dissolving and hydrogel-forming microneedle array platforms for transdermal delivery of bevacizumab. Bevacizumab recovery and transdermal permeation studies were conducted and analyzed using bevacizumab specific ELISA. Prototype microneedle-patches were tested <I>in vivo</I> in Sprague-Dawley rats with serum, exterior lumbar and axial lymph nodes, spleen, and skin tissue concentrations of bevacizumab reported. This work represents the first example of high dose transdermal delivery of an antibody therapeutic <I>in vivo</I> using dissolving and hydrogel-forming microneedle platforms. Basic pharmacokinetic parameters are described including hydrogel-forming microneedles: <I>C</I><SUB>max</SUB> 358.2 ± 100.4 ng/mL, <I>T</I><SUB>max</SUB> 48 h, AUC 44357 ± 4540, and <I>C</I><SUB>ss</SUB> 942 ± 95 ng/mL, highlighting the potential for these devices to provide sustained delivery of antibody therapeutics to the lymph and systemic circulation. Targeted delivery of chemotherapeutic agents to the lymphatic system by MN technology may provide new treatment options for cancer metastases.</P> [FIG OMISSION]</BR>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
